SAN

98.64

+1.9%↑

216.9

+1.02%↑

MRK1

154.65

+1.81%↑

SHL.DE

48.28

+0.81%↑

UCB

180.45

+1.98%↑

SAN

98.64

+1.9%↑

216.9

+1.02%↑

MRK1

154.65

+1.81%↑

SHL.DE

48.28

+0.81%↑

UCB

180.45

+1.98%↑

SAN

98.64

+1.9%↑

216.9

+1.02%↑

MRK1

154.65

+1.81%↑

SHL.DE

48.28

+0.81%↑

UCB

180.45

+1.98%↑

SAN

98.64

+1.9%↑

216.9

+1.02%↑

MRK1

154.65

+1.81%↑

SHL.DE

48.28

+0.81%↑

UCB

180.45

+1.98%↑

SAN

98.64

+1.9%↑

216.9

+1.02%↑

MRK1

154.65

+1.81%↑

SHL.DE

48.28

+0.81%↑

UCB

180.45

+1.98%↑

Home・Aktien・Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi SA

Geschlossen

Branche Gesundheitswesen

79.5 1.86

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

79.3

Max

79.65

Schlüsselkennzahlen
By Trading Economics
Einkommen	15M
Verkäufe	-297M 151M
KGV Branchendurchschnitt	24.61 106.547
EPS	0.292
Gewinnspanne	9.896
EBITDA	26M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+23.9 upside

Dividenden
By Dow Jones
Nächstes Ergebnis	7. Nov. 2024

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	137M 4.1B
Vorheriger Eröffnungskurs	77.64
Vorheriger Schlusskurs	79.5

Nachrichtenstimmung

By Acuity

100%

371 / 389 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bullish Evidence

76.2 / 80.2 Unterstützung & Widerstand

Laboratorios Farmaceuticos Rovi SA Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

1. Nov. 2024, 22:50 UTC

Heiße Aktien

Stocks to Watch: Nvidia, Intel, Sherwin-Williams, Dow, Nuwellis

1. Nov. 2024, 22:43 UTC

Wichtige Markttreiber

Nvidia, Sherwin-Williams Shares Up on Addition to DJIA

1. Nov. 2024, 22:13 UTC

Wichtige Markttreiber

Chewy Up 5% on S&P MidCap 400 Inclusion

1. Nov. 2024, 21:39 UTC

Ergebnisse

Insurance Company Chubb Projects Up to $300 Million Pre-Tax Loss on Hurricane

2. Nov. 2024, 13:53 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

Warren Buffett's Berkshire Hathaway Slashes Apple Stake Again -- Update

2. Nov. 2024, 13:44 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

Berkshire Sold 25% of Its Apple Stock in the Third Quarter -- Barrons.com

2. Nov. 2024, 13:00 UTC

Ergebnisse

China's EV Makers Set Sights on Latin America in Global Expansion -- WSJ

2. Nov. 2024, 12:58 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

Berkshire Sold 25% of Its Apple Stock in the Third Quarter -- Barrons.com

2. Nov. 2024, 12:48 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

Warren Buffett's Berkshire Hathaway Slashes Apple Stake Again -- WSJ

2. Nov. 2024, 12:32 UTC

Ergebnisse

Berkshire Profits Fell 6% in Third Quarter. The Buybacks Are on Pause. -- Barrons.com

2. Nov. 2024, 12:28 UTC

Akquisitionen, Fusionen, Übernahmen

Berkshire Sold 25% of Its Apple Stock in the Third Quarter -- Barrons.com

2. Nov. 2024, 12:17 UTC

Ergebnisse

Berkshire Profits Fell 6% in Third Quarter. The Buybacks Are on Pause. -- Barrons.com

2. Nov. 2024, 12:00 UTC

Ergebnisse

Berkshire Hathaway 3Q EPS $18272.00 >BRKA

2. Nov. 2024, 12:00 UTC

Ergebnisse

Berkshire Hathaway 3Q BNSF Operating Earnings $1.38B >BRKA

2. Nov. 2024, 12:00 UTC

Ergebnisse

Berkshire Hathaway 3Q Berkshire Hathaway Energy Company Operating Earnings $1.63B >BRKA

2. Nov. 2024, 12:00 UTC

Ergebnisse

Berkshire Hathaway 3Q Insurance-Underwriting Operating Earnings $750M >BRKA

2. Nov. 2024, 12:00 UTC

Ergebnisse

Berkshire Hathaway 3Q Other Operating Loss $877M >BRKA

2. Nov. 2024, 12:00 UTC

Ergebnisse

Berkshire Hathaway 3Q Insurance-Investment Income Operating Earnings $3.66B >BRKA

2. Nov. 2024, 12:00 UTC

Ergebnisse

Berkshire Hathaway 3Q Net $26.25B >BRKA

2. Nov. 2024, 12:00 UTC

Ergebnisse

Berkshire Hathaway 3Q Other Controlled Businesses Operating Earnings $3.34B >BRKA

2. Nov. 2024, 12:00 UTC

Ergebnisse

Berkshire Hathaway 3Q Non-Controlled Businesses Operating Earnings $199M >BRKA

2. Nov. 2024, 12:00 UTC

Ergebnisse

Berkshire Hathaway 3Q Operating Earnings $10.09B >BRKA

2. Nov. 2024, 12:00 UTC

Ergebnisse

Berkshire Hathaway 3Q Investment, Derivative Gains $16.16B >BRKA

2. Nov. 2024, 09:30 UTC

Peer-Vergleich

Kursveränderung

Laboratorios Farmaceuticos Rovi SA Prognose

Kursziel

By TipRanks

23.9% Vorteil

12-Monats-Prognose

Durchschnitt 99 EUR 23.9%

Hoch 104 EUR

Tief 94 EUR

Basierend auf 2 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Laboratorios Farmaceuticos Rovi SA – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

2 ratings

Buy

Halten

Sell

Basierend auf 2 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Laboratorios Farmaceuticos Rovi SA – Dist abgegeben haben.

Technischer Score

By Trading Central

76.2 / 80.2Unterstützung & Widerstand

Recent bullish events outweigh bearish events.

All events are bullish.

Stimmung

By Acuity

371 / 389 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

EBITDA

Betriebsergebnis

Über Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos ROVI SA (ROVI) is a Spain-based company principally engaged in the pharmaceutical industry. The Company’s main activities include the development and commercialization, nationwide and abroad, of medicines and drugs. Its products are structured into three fields: Diagnostic, which offers contrast mediums for use in magnetic resonance, ultrasound and X-ray diagnostics; Prescription, which distributes medicines under such brands as Hibor, Osseor, Hepadren, Pneumovax-23, Glufan, Corlentor, Exxiv, Calcio y Vitamina D3 Rovi and Absorcol, among others; and Over The Counter (OTC), which comprises the Perspirex, Enerzona, Dentimelo and ColdPack brands. The Company owns such fully consolidated subsidiaries as Gineladius SL, Frosst Iberica SA, Rovi Contract Manufacturing SL and Bertex Pharma GmbH, among others.